Spatial immune ecosystems govern therapeutic response in HER2-low breast cancer

HER2 low breast cancer represents a clinically important but biologically heterogeneous disease state, and the spatial immune programs underlying therapeutic response remain poorly understood.

HER2 low breast cancer represents a clinically important but biologically heterogeneous disease state, and the spatial immune programs underlying therapeutic response remain poorly understood. Here, we used single-cell spatial transcriptomics to characterize HER2 low and HER2…